Director Zheng Qinlong: Why Genetic Testing Is Growing Critical in Leukemia Diagnosis & Treatment
- Elva Chen
- 1 day ago
- 4 min read
How does genetic testing advance leukemia care? Which gene variants demand close attention? What should patients bear in mind when undergoing genetic testing? In this article, Director Zheng Qinlong from the Molecular Diagnostic Laboratory of Gaobo Diagnostic Center / Beijing Boren Hospital thoroughly explains the vital role of genetic testing in leukemia management.
Leukemia is a common hematological malignancy with greatly improved therapeutic outcomes in recent years. Most patients with standard subtypes can achieve remission following guideline-based therapy.
Nevertheless, leukemia features extreme genetic heterogeneity. Every patient’s leukemia carries distinct genetic alterations. Such differences explain why some patients respond excellently to conventional chemotherapy, while others suffer relapse or poor treatment efficacy.
Medically speaking, tumors originate fundamentally from genetic defects that allow abnormal cells to evade bodily clearance and proliferate uncontrollably.
Two key factors underpin this process:
Intrinsic tumor characteristics: Different gene mutations lead to varying drug sensitivity.
Patient-specific factors, including immune clearance capacity and DNA repair function.
Clinicians must fully grasp both disease traits and individual patient conditions. Standard regimens work well for typical cases, yet high-risk, refractory or relapsed leukemia requires personalized therapy instead of one-size-fits-all protocols.
Nowadays, targeted drugs, immunotherapy, CAR-T and other advanced modalities are widely available. Genetic testing delivers pivotal evidence to select the optimal treatment approach.
Core Value 1: Precise Diagnosis Serves as the First Step of Treatment
Accurate diagnosis requires integrated data from four testing tiers:
Morphological examination (microscopic cellular observation)
Immunophenotyping via flow cytometry
Chromosome cytogenetic analysis
Molecular genetic testing (e.g., next-generation sequencing)
Rapid advances in genetic testing enable comprehensive profiling of tumor gene variants combined with cytogenetics and FISH. This holistic analysis clarifies molecular disease mechanisms to underpin precise diagnosis and treatment planning.
Moreover, inherited susceptibility genes may raise leukemia risk or alter treatment response. Combining tumor mutations with individual genetic background helps stratify malignancy grade and prognostic risk, while guiding targeted drug selection.
Core Value 2: Minimal Residual Disease (MRD) Monitoring Predicts Treatment Success
Persistent residual leukemic cells post-treatment determine clinical outcomes. These residual malignant cells are often drug-resistant, stemming from insufficient dosing or incomplete treatment coverage. Higher residual burden correlates with elevated relapse risk and tougher salvage therapy.
High-sensitivity molecular testing detects trace residual leukemic cells to guide subsequent intervention. Detectable MRD prompts timely targeted therapies such as antibody-drug conjugates or CAR-T cell therapy to eliminate remaining tumor cells.
If genetic screening reveals congenital immune deficiency or defective DNA repair, allogeneic hematopoietic stem cell transplantation should be prioritized early to secure long-term survival, as standard chemotherapy rarely achieves cure.
Leukemia care has entered the precision medicine era. Early genetic profiling at initial diagnosis streamlines clinical decision-making and drastically boosts therapeutic efficacy.
Low-risk gene signatures allow reduced-intensity chemotherapy to minimize developmental damage, while high-risk mutations call for prompt escalation to targeted or immunotherapy.
Genetic testing optimizes regimen selection, avoids unnecessary interventions and cuts long-term medical costs, making it indispensable for all leukemia patients.
Three Major Benefits of Genetic Testing for Hematologic Malignancies
1. Foundation of Individualized Precision Therapy
Historically, clinicians relied solely on microscopy and routine markers to assess treatment response. Today, distinct mutation combinations drive divergent therapeutic effects and prognoses.
Case example: An adult B-cell acute lymphoblastic leukemia (B-ALL) patient tested positive for BCR-ABL1 fusion via routine 40+ fusion gene panels and received Ph-positive B-ALL targeted therapy. Persistent MRD was later traced to a second adverse fusion gene missed by initial limited screening. Early full-spectrum genetic testing would have enabled an optimized first-line regimen.
Modern molecular subtyping replaces experience-based judgment to stratify malignancy risk and guide treatment intensification. Global clinical trials confirm reduced chemotherapy intensity is safe for low-mutation leukemias, representing risk-adapted personalized care.
2. Three Clinically Significant Gene Categories
Clinicians prioritize three groups of genetic alterations:
Common mutations with definitive prognostic stratification value
Variants directing targeted drug administration
Biomarkers for minimal residual disease surveillance
High-frequency mutations are screened at initial diagnosis for balanced cost and clinical yield. Expanded sequencing panels are ordered for sustained MRD or non-remitting disease to uncover novel resistance mutations.
Interpretation of single mutations depends on leukemia subtype, treatment plan and patient status. For instance, TP53 mutations generally indicate poor prognosis, yet favorable outcomes can still be achieved with intensive regimens for Burkitt lymphoma.
Tumors evolve dynamically under therapeutic pressure, acquiring new drug-resistant mutations. Therefore, comprehensive serial genetic monitoring throughout treatment is mandatory.
Genetic reports must integrate clinical context, delivering actionable insights including prognostic grading, targeted therapy recommendations and true MRD differentiation from benign irrelevant variants. Result interpretation also accounts for technical limitations, mutation functional impact and prior treatment history.
3. Practical Recommendations for Reliable Genetic Testing
For clinicians: Strengthen communication with molecular laboratories to dynamically adjust treatment strategies. Precision medicine relies on high-quality testing, requiring consistent feedback loops between clinical and lab teams.
For patients: Choose qualified, experienced diagnostic institutions. Testing quality outweighs price. Low-cost limited-depth sequencing often misses critical low-frequency mutations, skewing treatment decisions.
The value of testing does not correlate with panel size; priority lies in whether detected variants can guide therapy, stratify prognosis or monitor residual disease.
Conclusion
Genetic testing acts as intelligence gathering for leukemia treatment, with its accuracy and clinical utility directly shaping therapeutic pathways. A high-quality molecular report features three hallmarks:
Actionable clinical conclusions including clear prognosis and targeted therapy guidance
Sufficient sequencing depth to capture low-frequency pathogenic mutations
Dynamic clinical correlation to adjust risk assessment as disease progresses
Integrating genetic results into routine clinical practice enables the safest, most effective and cost-efficient personalized treatment regimens for each patient.
Comments